Eli Lilly and Company $LLY Shares Acquired by Constitution Capital LLC

Constitution Capital LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 626.9% in the second quarter, HoldingsChannel reports. The firm owned 8,941 shares of the company’s stock after purchasing an additional 7,711 shares during the quarter. Eli Lilly and Company accounts for about 5.5% of Constitution Capital LLC’s holdings, making the stock its 3rd largest holding. Constitution Capital LLC’s holdings in Eli Lilly and Company were worth $10,724,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Fulton Bank N.A. raised its position in shares of Eli Lilly and Company by 3.1% in the second quarter. Fulton Bank N.A. now owns 14,349 shares of the company’s stock valued at $17,211,000 after purchasing an additional 434 shares during the period. Paladin Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 38.4% during the 2nd quarter. Paladin Wealth LLC now owns 677 shares of the company’s stock worth $812,000 after buying an additional 188 shares during the period. Kraft Davis & Associates LLC boosted its holdings in shares of Eli Lilly and Company by 4.8% during the 2nd quarter. Kraft Davis & Associates LLC now owns 374 shares of the company’s stock worth $457,000 after buying an additional 17 shares during the period. Financial Management Professionals Inc. grew its stake in Eli Lilly and Company by 2.6% in the 2nd quarter. Financial Management Professionals Inc. now owns 933 shares of the company’s stock valued at $1,119,000 after buying an additional 24 shares during the last quarter. Finally, First Bank & Trust grew its stake in Eli Lilly and Company by 20.2% in the 2nd quarter. First Bank & Trust now owns 1,213 shares of the company’s stock valued at $1,455,000 after buying an additional 204 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,230.00 on Tuesday. The firm has a 50-day moving average price of $1,162.38 and a two-hundred day moving average price of $1,048.95. Eli Lilly and Company has a 12-month low of $625.90 and a 12-month high of $1,249.45. The company has a market capitalization of $1.16 trillion, a P/E ratio of 41.28, a P/E/G ratio of 1.38 and a beta of 0.51. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. During the same period last year, the firm earned $6.31 earnings per share. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts anticipate that Eli Lilly and Company will post 36.77 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a research report on Friday. Royal Bank Of Canada upped their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research report on Wednesday, July 8th. Jefferies Financial Group increased their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Wolfe Research reissued an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,292.18.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Lilly’s Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. The authorization is the pill’s first European approval and gives Lilly access to a large potential market supported by its global commercial infrastructure. Eli Lilly’s GLP-1 Pill Secures First European Milestone
• Positive Sentiment: The approval also strengthens Lilly’s competitive position against Novo Nordisk in obesity drugs. Analysts and investors are increasingly focused on whether a convenient oral treatment can expand the GLP-1 market and increase patient adoption. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Lilly’s latest quarterly performance remains a major support for the stock. Second-quarter revenue rose 47.7% year over year to approximately $23.0 billion, while adjusted EPS of $8.38 exceeded the $6.40 consensus estimate. Management set fiscal 2026 EPS guidance of $35.50 to $36.50, highlighting continued confidence in demand for its portfolio. Eli Lilly Posts Blowout Growth and Raises Its Outlook
• Neutral Sentiment: Investors are also weighing potential U.S. policies encouraging domestic pharmaceutical manufacturing. Lilly may be relatively well positioned if reshoring requirements favor companies with significant U.S. production capacity, although the policy details and costs remain uncertain. Eli Lilly vs. Novo Nordisk
• Neutral Sentiment: Sector rotation toward innovative healthcare companies, as investors seek alternatives to highly valued technology stocks, provided an additional supportive backdrop for Lilly. Jim Cramer Highlights Pharmaceutical Giants
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares worth approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The transaction may attract attention, but its scheduled nature reduces its significance as a signal about Lilly’s outlook. SEC Form 4 Filing

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.